{"ModuleTitle": "Company Description", "CompanyName": "Acasti Pharma, Inc.", "Symbol": "ACST", "Address": "545 PROMENADE DU CENTROPOLIS SUITE 100, LAVAL, H7T 0A3, Canada", "Phone": "(450) 687-2262", "Industry": "Major Pharmaceuticals", "Sector": "Health Care", "Region": "North America", "CompanyDescription": "Acasti was incorporated on February 1, 2002 under Part 1A of the Companies Act\r\n(Qu\u00e9bec) under the name \"9113-0310 Qu\u00e9bec Inc.\". On February 14, 2011, the\r\nBusiness Corporations Act (Qu\u00e9bec) (\"QBCA\") came into effect and replaced the\r\nCompanies Act (Qu\u00e9bec). We are now governed by the QBCA. On August 7, 2008,\r\npursuant to a Certificate of Amendment, we changed our name to \"Acasti Pharma\r\nInc.\", our share capital description, the provisions regarding the restriction\r\non securities transfers and our borrowing powers. On November 7, 2008, pursuant\r\nto a Certificate of Amendment, we changed the provisions regarding our borrowing\r\npowers. We became a reporting issuer in the Province of Qu\u00e9bec on November 17,\r\n2008.\r\n\r\n  - 23 -  \r\n\r\n\r\n \r\n\r\nAcasti's head and registered office is located at 545 Promenade du Centropolis,\r\nSuite 100, Laval, Qu\u00e9bec H7T 0A3. We currently employ 28 full-time employees\r\nwith the majority working out of our headquarters in Laval and our laboratory in\r\nSherbrooke.&nbsp;&nbsp;... <a href=\"http://secfilings.nasdaq.com/edgar_conv_html%2f2019%2f06%2f26%2f0001171843-19-004174.html#FIS_COMPANY_INFORMATION\" target=\"_blank\">More</a> ...&nbsp;&nbsp;\r\n", "KeyExecutives": [{"name": "Janelle D'Alvise", "title": "President, Chief Executive Officer & Director"}, {"name": "Pierre Lemieux", "title": "Chief Operating & Scientific Officer"}], "Number_of_employees": ["NO INFO"], "Subsidiaries": ["NO INFO"]}